Wuxi Biortus Biosciences completes round A financing with USD15m investment headed by Bayland Capital
16 November 2020 -

Wuxi Biortus Biosciences Co. Ltd, a company involved in structural biology service for drug discovery, has completed round A financing with USD15m investment headed by Bayland Capital, it was reported on Friday.

The funds will be utilised to set up a global cryo-EM innovation centre.

With the support from the round A fund, the company is upgrading its cryo-EM platform to a research hub named 'Biortus Cryo-EM'. The research hub is being built at Wuxi International Life Science Innovation Campus (I·Campus) in partnership with Wuxi Municipal Government, Wuxi New District and global biopharmaceutical company AstraZeneca.

Phase one construction of the hub is to be completed in January of 2021 with the first three sets of newly purchased cryo-EM instruments, including a fully loaded Titan Krios 300kV electron microscope. Over the next three years, Biortus Cryo-EM is to add around five units of high-end electron microscopes to further expand its capacity.